Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Aara Research Center

Neither a doctor nor a teaching hospital

Research payments

$955,049

158 payments

Through program year 2025, Aara Research Center is reported as receiving $955,049 in research payments, across 158 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,715 5
2024 Research $507 3
2023 Research $10,147 10
2022 Research $51,623 32
2021 Research $740,791 58
2020 Research $91,650 31
2019 Research $58,615 19

Breakdown

Who paid Research payments · program years 2019–2025
  1. Grifols Therapeutics LLC $514,205 20 payments
  2. CSL Behring $385,658 123 payments
  3. Novartis Pharmaceuticals Corporation $36,309 2 payments
  4. BioCryst Pharmaceuticals, Inc. $9,113 4 payments
  5. Octapharma USA, Inc. $8,411 6 payments
  6. Ionis Pharmaceuticals, Inc. $1,020 1 payment
  7. Teva Pharmaceuticals USA, Inc. $273 1 payment
  8. Merck Sharp & Dohme Corporation $61 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20 Biweekly Dosing in Treatment-Experienced Subjects and LoadingMaintenance Dosing in Treatment-Nave Subjects With Primary Immunodeficiency $440,467 16 payments
  2. A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema $164,618 15 payments
  3. An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema $154,755 45 payments
  4. A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG compared to Gamunex-C in Subjects with Primary Humoral Immunodeficiency $51,147 2 payments
  5. A Multicenter, Randomized, Placebo-controlled, Parallel-arm Study to Investigate the Efficacy, Pharmacokinetics, and Safety of CSL312 in Subjects With Hereditary Angioedema $50,482 56 payments
  6. A 12 Week Multicenter Randomized Double Blind Placebo Controlled Study to Assess the Efficacy and Safety of Qaw039 When Added to Standard of Care Asthma Therapy in Patients With Uncontrolled Asthma $36,309 2 payments
  7. A Phase 3, Multicenter, Open-label, Single-sequence, Cross-over, Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of IVIG-PEG compared to Gamunex-C in Subjects with Primary Humoral Immunodeficiency $22,591 2 payments
  8. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Efficacy and Safety of Subcutaneous Administration of CSL312 in the Prophylactic Treatment of Hereditary Angioedema $15,568 5 payments
  9. An open-label study to evaluate the long-term safety of daily oral BCX7353 in subjects with Type I and II hereditary angioedema $9,113 4 payments
  10. Gam5-28 $5,938 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record